<DOC>
<DOCNO>en.3.376.309.2007.6.25</DOCNO>
<TITLE> High Court to hear Alzheimer's drugs case </TITLE>
<TEXT>
 LONDON, June 25 (bdnews24.com/Reuters) - Drug manufacturers went to the High Court on Monday to challenge a decision by the medicines cost-effectiveness watchdog NICE to restrict access to Alzheimer's drugs on the National Health Service. Two drugs companies are challenging the process by which the National Institute for Health and Clinical Excellence reached its decision to ban anti-dementia medicines for NHS patients with newly diagnosed mild Alzheimer's disease. It is the first time that the agency in charge of deciding which medicines are offered in the state health system in England and Wales has faced such legal action. In May, the High Court granted a request to fast-track the judicial review at the request of Eisai Co Ltd and Pfizer Inc which jointly market the top-selling such medicine Aricept. NICE believes drugs like Aricept do not make enough of a difference to be used at all stages of Alzheimer's disease. In future, it wants them to be prescribed only for a minority of patients with disease of moderate severity. Anti-cholinesterase drugs such as Aricept can help but not cure some Alzheimer's patients. They are widely used in other countries, but NICE experts calculate that their cost -- around 1,000 pounds per patient a year -- means they are not cost-effective for most patien
</TEXT>
</DOC>
